Hand-out
Press Releases
Vensica Medical Secures $11M in Funding to Support Phase 2 Trials for Overactive Bladder Treatment
Backed by IBF, Merz, and Laborie, Vensica to Advance Needle-Free Delivery of Botulinum Toxin A (Xeomin®) for Minimally Invasive Treatment